Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity of EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). This study was designed to evaluate the predictive value on gefitinib outcomes of a comprehensive panel of molecular parameters in advanced NSCLC patients EGFR and K-ras mutations were detected by direct sequencing on tumor DNA from paraffin embedded samples EGFR and HER2 gene copy number was assessed by FISH EGFR protein expression was quantified by immunohistochemistry. EGFR gene intron 1 polymorphism was assessed on genomic DNA isolated from venous whole blood samples Ninety-one patients were prospectively enrolled and the overall gefitinib response rate was 18 7% (2 complete and 15 partial responses) Sex (p = 0005), non-smoking status (p = 0010). skin toxicity (p = 0020). EGFR gene mutations (p <0.001) and EGFR FISH positivity (p = 0.016) were found to be associated with gefitinib response K-ras mutation was detected in only seven non-responder patients. The median overall survival was of 10 months Only non-smoking status and EGFR intron 1 polymorphism showed a statistically significant correlation with survival (p= 0.031 and 0044, respectively). In conclusion, we have confirmed the role of EGFR gene mutation as predictor of response to EGFR TKIs Moreover, EGFR gene copy number and, potentially, also EGFR intron 1 polymorphism could aid in better prediction of EGFR TKI responsiveness in advanced NSCLC. (C) 2009 Published by Elsevier Ireland Ltd